LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its interim results for the six months ended 30 June 2022 on Monday 26 September 2022. Investor presentation Paul Pagano, Chief Executive Officer, and David […]
LungLife AI, Inc. (the “Company” or “LungLife”) New York State approves LungLB® for commercial testing LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the New York State Department of Health (“NYSDOH”) has awarded LungLife a Clinical Laboratory Evaluation Program (“CLEP”) permit following their recent on-site audit, during […]
LungLife AI licensure/accreditation information posted here.